Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003
Executive Summary
Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use
You may also be interested in...
FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints
FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints
Eloxatin Has 38% Share Of First-Line Colorectal Cancer Market, Sanofi Says
Sanofi-Synthelabo's Eloxatin has taken a greater than one-third share of the first-line advanced colorectal cancer market from Camptosar ahead of FDA approval, Exec VP-Operations Hanspeter Spek said